- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gepotidacin Offers Safe and Effective Oral Alternative for Urogenital Gonorrhoea: Lancet

A new study published in The Lancet journal showed that Gepotidacin was non-inferior to the standard treatment of ceftriaxone plus azithromycin for urogenital Neisseria gonorrhoeae, with no new safety concerns reported. This highlights gepotidacin as a promising novel oral treatment option for uncomplicated urogenital gonorrhoea.
It has been demonstrated that gepotidacin, a first-in-class, bactericidal, triazaacenaphthylene antibiotic that prevents bacterial DNA replication, is both effective and well-tolerated when used to treat simple UTIs. Thus, to assess the safety and effectiveness of gepotidacin for the treatment of uncomplicated urogenital gonorrhea, Jonathan Ross and colleagues carried out this investigation.
This trial compared conventional therapy for uncomplicated urogenital gonorrhea (500 mg IM ceftriaxone + 1 g oral azithromycin) with oral gepotidacin (two 3000 mg doses, 10–12 hours apart). The participants were randomized 1:1, stratified by age, sex, and sexual orientation, and had to be at least 12 years old, weigh more than 45 kg, and have a proven or suspected infection. Microbiological success, or the culture-confirmed eradication of Neisseria gonorrhoeae at days 4–8, was the main endpoint, with a non-inferiority margin of −10%.
All participants randomly assigned to a study treatment who acquired at least one dose of their study treatment and were found to have ceftriaxone-susceptible N. gonorrhoeae isolated from the baseline culture of their urogenital specimen were evaluated for the primary outcome in the microbiological intention-to-treat (micro-ITT) population.
A total of 628 participants were randomized evenly to either ceftriaxone plus azithromycin or gepotidacin from October 2019 to October 2023 and 39% of them were lost to follow-up. There were 406 individuals in the micro-ITT population (204 receiving conventional treatment and 202 receiving gepotidacin).
The majority (92%) were men, and MSM made up a larger percentage (71%) than MSW (20%). 74% were White, 15% were Black/African American, and 17% were Hispanic or Latino. Non-inferiority was demonstrated by the microbiological success rates at test-of-cure, which were 92.6% in the gepotidacin group and 91.2% in the ceftriaxone + azithromycin group.
In neither group did urogenital N. gonorrhoeae persist. Mild to moderate gastrointestinal problems were the most common drug-related side events in the gepotidacin group. Neither group experienced any severe or major adverse effects. Overall, with no new safety issues, gepotidacin showed no inferiority to ceftriaxone with azithromycin for urogenital N. gonorrhoeae, providing a new oral treatment option for simple urogenital gonorrhea.
Source:
Ross, J. D. C., Wilson, J., Workowski, K. A., Taylor, S. N., Lewis, D. A., Gatsi, S., Flight, W., Scangarella-Oman, N. E., Jakielaszek, C., Lythgoe, D., Powell, M., Janmohamed, S., Absalon, J., & Perry, C. (2025). Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet, 405(10489), 1608–1620. https://doi.org/10.1016/S0140-6736(25)00628-2
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751